Scynexis Inc financial data

Symbol
SCYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1 Evertrust Plaza, 13 Th Floor, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400 % -6.72%
Quick Ratio 25.8 % +354%
Debt-to-equity 70.5 % -63.2%
Return On Equity -54.8 % -130%
Return On Assets -32.1 % -151%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.9M shares +1.99%
Common Stock, Shares, Outstanding 37.9M shares +2.06%
Entity Public Float 60.2M USD -64.4%
Weighted Average Number of Shares Outstanding, Basic 48.6M shares +1.52%
Weighted Average Number of Shares Outstanding, Diluted 48.6M shares +1.52%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 660K USD -62.5%
Research and Development Expense 32.7M USD +15.5%
Operating Income (Loss) -52.1M USD -171%
Nonoperating Income (Expense) 16M USD -14.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36.2M USD -150%
Income Tax Expense (Benefit) 274K USD
Net Income (Loss) Attributable to Parent -36.4M USD -150%
Earnings Per Share, Basic -0.76 USD/shares -153%
Earnings Per Share, Diluted -0.67 USD/shares -150%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.7M USD -34.8%
Cash, Cash Equivalents, and Short-term Investments 84.9M USD -19.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD -100%
Other Assets, Current 953K USD -49.7%
Assets, Current 80.5M USD -37.5%
Property, Plant and Equipment, Net 61K USD -77.5%
Operating Lease, Right-of-Use Asset 2.16M USD -10.8%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 99M USD -33.3%
Accounts Payable, Current 4.96M USD +42%
Accrued Liabilities, Current 5.51M USD -42.3%
Liabilities, Current 25.7M USD +53.2%
Operating Lease, Liability, Noncurrent 2.28M USD -14.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 40.5M USD -28.4%
Retained Earnings (Accumulated Deficit) -372M USD -10.9%
Stockholders' Equity Attributable to Parent 58.5M USD -36.4%
Liabilities and Equity 99M USD -33.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.01M USD +78.8%
Net Cash Provided by (Used in) Financing Activities 22K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 5.45M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 37.9M shares +2.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.3M USD -34.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 420K USD -74.7%
Deferred Tax Assets, Valuation Allowance 60.6M USD -41.4%
Deferred Tax Assets, Gross 60.6M USD -41.4%
Operating Lease, Liability 2.67M USD -10.8%
Lessee, Operating Lease, Liability, to be Paid 3.72M USD -16.3%
Operating Lease, Liability, Current 389K USD +19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759K USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 744K USD +1.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.05M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 774K USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 46.4M USD -47.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 361K USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 790K USD +2.07%
Operating Lease, Payments 726K USD +2.11%
Additional Paid in Capital 431M USD +0.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.92M USD +16%
Interest Expense 836K USD -85.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%